贝伐珠单抗联合FOLFOX化疗方案治疗转移性结肠癌的疗效及对免疫功能和生活质量的影响

Effect of bevacizumab combined with FOLFOX chemotherapy regimen on the efficacy,immune function and quality of life in patients with metastatic colon cancer

目的探讨贝伐珠单抗联合奥沙利铂+亚叶酸钙+5-氟尿嘧啶(FOLFOX)化疗方案治疗转移性结肠癌的疗效及对免疫功能和生活质量的影响。方法将78例转移性结肠癌患者根据治疗方式分为对照组(n=35,FOLFOX化疗方案)和观察组(n=43,贝伐珠单抗联合FOLFOX化疗方案)。比较两组患者疗效、免疫指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平、欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)评分、治疗过程中的不良反应。结果观察组患者客观缓解率(ORR)、疾病控制率(DCR)分别为44.19%(19/43)、76.74%(33/43),均高于对照组的22.86%(8/35)、51.43%(18/35),差异均有统计学意义(P﹤0.05)。治疗后,观察组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均明显高于对照组,CD8^(+)水平明显低于对照组,差异均有统计学意义(P﹤0.01)。治疗后,观察组患者EORTC QLQ-C30量表中功能领域各项评分及总体健康状况评分均高于对照组,症状领域评分均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者各不良反应发生情况比较,差异均无统计学意义(P﹥0.05)。结论贝伐珠单抗联合FOLFOX化疗方案治疗转移性结肠癌患者近期疗效好,显著改善患者免疫系统功能,提高患者的生活质量,不增加不良反应。

Objective To explore the effect of bevacizumab combined with FOLFOX chemotherapy on the efficacy,immune function and quality of life of patients with metastatic colon cancer.Method According to the treatment method,the clinical data of 78 patients with metastatic colon cancer were divided into the control group(n=35,FOLFOX chemotherapy regimen)and the observation group(n=43,bevacizumab combined with FOLFOX chemotherapy regimen).The treatment efficacy,immune indicators(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)scale score,and adverse reactions during the treatment were compared between the two groups.Result The objective response rate(ORR)(44.19%)and disease control rate(DCR)(76.74%)of the observation group were higher than that of the 22.86% and 51.43% of the control group(P<0.05).After treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+) in the observation group were higher than those in the control group,CD8^(+)was lower than that of the control group(P<0.01).After treatment,the scores of functional areas and overall health status of the observation group were higher than those of the control group,and the scores of the symptom area were lower than those of the control group(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion Bevacizumab combined with FOLFOX chemotherapy regimen has good short-term curative effect in the treatment of patients with metastatic colon cancer,significantly improves the patients’immune system function,improves the patients’quality of life,and it does not increase adverse reactions.